- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kyverna Therapeutics Inc (KYTX)
Kyverna Therapeutics Inc stock price live, this page displays NASDAQ KYTX stock exchange data. View the KYTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Kyverna Therapeutics Inc real time stock price chart below.
What Is the Kyverna Therapeutics Inc Stock Price Today?
The Kyverna Therapeutics Inc stock price today is 6.22.
What Is the Stock Symbol for Kyverna Therapeutics Inc?
The stock symbol for Kyverna Therapeutics Inc is "KYTX."
What Stock Exchange Does Kyverna Therapeutics Inc Trade On?
Kyverna Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Kyverna Therapeutics Inc a Good Stock to Buy?
Determining whether Kyverna Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KYTX quote. (ISIN: US5019761049)
What Is the Kyverna Therapeutics Inc Stock Price Today?
The Kyverna Therapeutics Inc stock price today is 6.22.
What Is the Stock Symbol for Kyverna Therapeutics Inc?
The stock symbol for Kyverna Therapeutics Inc is "KYTX."
What Stock Exchange Does Kyverna Therapeutics Inc Trade On?
Kyverna Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Kyverna Therapeutics Inc a Good Stock to Buy?
Determining whether Kyverna Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the KYTX quote. (ISIN: US5019761049)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.17
6.75
52 wk Range
5.30
13.67
KYTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.176.75
52 wk Range
5.3013.67
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KYTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
30.40
Upside
+388.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
Why is Kyverna Therapeutics stock surging today?- Investing.com
Form 8K Kyverna Therapeutics Inc For: 24 September- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 30.40
(+388.75% Upside)
Earnings
Latest Release
Aug 11, 2026
EPS / Forecast
-0.63 / -1.08
Revenue / Forecast
-- / --
Compare KYTX to Peers and Sector
Metrics to compare | KYTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKYTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −4.5x | −0.4x | |
PEG Ratio | −0.12 | −0.03 | 0.00 | |
Price/Book | 2.3x | 2.3x | 2.6x | |
Price / LTM Sales | - | 13.1x | 3.0x | |
Upside (Analyst Target) | 366.3% | 134.8% | 56.4% | |
Fair Value Upside | Unlock | 18.4% | 7.9% | Unlock |
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Kyverna Therapeutics (KYTX) Stock Price Today?
The Kyverna Therapeutics stock price today is 6.22 USD.
What Stock Exchange Does Kyverna Therapeutics Trade On?
Kyverna Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Kyverna Therapeutics?
The stock symbol for Kyverna Therapeutics is "KYTX."
What Is the Kyverna Therapeutics Market Cap?
As of today, Kyverna Therapeutics market cap is 403.22M USD.
What Is Kyverna Therapeutics's Earnings Per Share (TTM)?
The Kyverna Therapeutics EPS (TTM) is -2.88.
When Is the Next Kyverna Therapeutics Earnings Date?
Kyverna Therapeutics will release its next earnings report on Nov 18, 2026.
From a Technical Analysis Perspective, Is KYTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Kyverna Therapeutics Stock Split?
Kyverna Therapeutics has split 0 times.
How Many Employees Does Kyverna Therapeutics Have?
Kyverna Therapeutics has 149 employees.
What is the current trading status of Kyverna Therapeutics (KYTX)?
As of Oct 02, 2026, Kyverna Therapeutics (KYTX) is trading at a price of 6.22 USD, with a previous close of 6.52 USD. The stock has fluctuated within a day range of 6.17 USD to 6.75 USD, while its 52-week range spans from 5.30 USD to 13.67 USD.
What Is Kyverna Therapeutics (KYTX) Price Target According to Analysts?
The average 12-month price target for Kyverna Therapeutics is 30.40 USD, with a high estimate of 33 USD and a low estimate of 25 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +388.75% Upside potential.
What Is the KYTX Premarket Price?
KYTX's last pre-market stock price is 6.15 USD. The pre-market share volume is 4,030.00, and the stock has decreased by -0.37, or -5.67%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.